Daily BriefsHealthcare

Health Care: Pharmaessentia Corp and more

In today’s briefing:

  • Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow

Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow

By Tina Banerjee

  • Pharmaessentia Corp (6446 TT) received FDA approval for its rare cancer drug, BESREMi, which has superior clinical efficacy over the existing standard of care.
  • The drug has already been approved in 17 countries in EU, Taiwan, and South Korea. It is also being developed for several other indications, with license expected in next year.
  • BESREMi’s continued success in the EU markets since its launch in 2019 has enhanced my conviction on the commercial accomplishment of BESREMi in the U.S.

Before it’s here, it’s on Smartkarma